UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
September 9, 2004
Date of Report (Date of earliest event reported)
-------------------------------------------------------------------------------
ANTIGENICS INC
(Exact name of registrant as specified in its charter)
-------------------------------------------------------------------------------
DELAWARE 000-29089 06-1562417
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
630 Fifth Avenue, Suite 2100
New York, NY 10111 10111
(Address of principal executive offices) (Zip Code)
212-994-8200
(Registrant's telephone number, including area code)
-------------------------------------------------------------------------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS
On September 10, 2004, Antigenics Inc. (the "Company") announced the
appointment of Alastair J. J. Wood, MD, to its board of directors. There was no
arrangement or understanding pursuant to which Dr. Wood was elected as a
director, and there are no related party transactions between the Company and
Dr. Wood. Dr. Wood will serve on the Corporate Governance Committee of the
Company's Board of Directors.
On September 10, 2004, the Company issued a press release announcing the
election of Dr. Wood as a new director to the Company's Board of Directors. The
full text of the press release is attached as Exhibit 99.1 to this Form 8-K.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits:
99.1 Press Release dated September 10, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANTIGENICS INC.
Date: September 10, 2004
By: /s/ Garo H. Armen
----------------------------------
Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer
EXHIBIT INDEX
The following designated exhibits are filed herewith:
Exhibits:
99.1 Press Release dated September 10, 2004